Drug Trial Radar · NCT02888704
Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Jul 2016
Primary completion
Dec 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- EHL Bio Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of autologous mesenchymal stem cells. The study is composed of two steps. Step 1 is to determine clinically proper dose capacity of the ADSTEM Inj. and step 2 is to evaluate exploratory efficacy of the ADSTEM Inj. at the proper dose.
Conditions
- Atopic Dermatitis
Interventions
ADSTEM Inj. (Adult human mesenchymal stem cells)Drug
Comparison of different dosages of the drug in the aspect of safety and efficacy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03Time frame: 12 weeks follow-up after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungnam National University Hospital
Daejeon, Chungcheongnam-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.